An overview on the current status of cancer nanomedicines.

Autor:	Jabir NR; a King Fahd Medical Research Center , King Abdulaziz University , Jeddah , Saudi Arabia., Anwar K; b School of Life Sciences , Jawaharlal Nehru University , New Delhi , India., Firoz CK; a King Fahd Medical Research Center , King Abdulaziz University , Jeddah , Saudi Arabia., Oves M; c Center of Excellence in Environmental Studies , King Abdulaziz University , Jeddah , Saudi Arabia., Kamal MA; a King Fahd Medical Research Center , King Abdulaziz University , Jeddah , Saudi Arabia., Tabrez S; a King Fahd Medical Research Center , King Abdulaziz University , Jeddah , Saudi Arabia.
Jazyk:	angličtina
Zdroj:	Current medical research and opinion [Curr Med Res Opin] 2018 May; Vol. 34 (5), pp. 911-921. Date of Electronic Publication: 2018 Jan 22.
DOI:	10.1080/03007995.2017.1421528
Abstrakt:	Purpose: Cancer remains a significant cause of morbidity and mortality across the globe. A recent report suggests around 14.1 million new cases and 8.2 million cancer-related deaths, which are expected to reach 21.7 million and 13 million by 2030 worldwide, respectively. Materials and Methods: Because of highly complex mechanisms of cancer progression, it is important to explore and develop new innovative technologies which are more efficient compared with presently available treatment options. Results: Currently, chemotherapy, radiation and surgery are the most commonly used cancer treatment methods. In the last decade, nanomedicine emerged as an alternative treatment option that uses specific drug-delivery systems, improves efficacy of drugs and reduces detrimental side effects to normal tissues. Conclusion: In this review, we have summarized cancer nanomedicines (active and passive drug delivery) available in the market. We have also discussed other nanomedicines that are at different stages of clinical trials.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu